Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it ... in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small ...

but the company's strategic move to protect the franchise with a longer acting formulation has proved prescient. Moving forward, it is expected that sales growth momentum in DUPIXENT and LIBTAYO ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

Regeneron develops and commercializes Libtayo globally. About Immuneering Corporation Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...